Physician profile
Lesley Abbott
NPI 1265511315
$638.12
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $504 · 2020: $32.42 · 2021: $62.42 · 2022: $39.07.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $261.11 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.57 | 2019-2020 | |
| Lilly USA, LLC | $52.36 | 2019 | |
| Merck Sharp & Dohme LLC | $48.85 | 2019 | |
| Pfizer INC. | $40.16 | 2019 | |
| Novartis Pharmaceuticals Corporation | $32.55 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.08 | 2019 | |
| Coloplast Corp | $22.68 | 2019 | |
| Sunovion Pharmaceuticals INC. | $20.91 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.75 | 2019 | |
| Abbott Laboratories | $14.61 | 2021 | |
| Horizon Therapeutics Plc | $13.66 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $10.83 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lesley Abbott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.